Ocugen to Highlight Retinal Gene Therapy Progress at Clinical Showcase
Key Insights
Ocugen will present updates on the Phase 3 liMeliGhT trial for retinitis pigmentosa (search) and new Phase 1/2 data on November 12.
Preliminary safety and efficacy data from the Phase 1/2 ArMaDa trial for geographic atrophy (search) will be shared during the showcase.
The event will also feature a clinical update on the Phase 1/2 GARDian trial for Stargardt disease (search), offering insights into the treatment's progress.
Ocugen, Inc. (NASDAQ: OCGN) will host an in-person Clinical Showcase on Tuesday, November 12, 2024, in New York City, to highlight advancements in its retinal gene therapy clinical trials. The event will feature updates on the Phase 3 liMeliGhT trial for retinitis pigmentosa (search) (RP), preliminary data from the Phase 1/2 ArMaDa trial for geographic atrophy (search) (GA), and progress from the Phase 1/2 GARDian study for Stargardt disease (search).
Retinitis Pigmentosa: OCU400 Phase 3 liMeliGhT Trial
The showcase will provide a clinical update on the Phase 3 liMeliGhT trial evaluating OCU400 for retinitis pigmentosa (search). RP is a group of genetic disorders that affect the retina's ability to respond to light, leading to progressive vision loss. The liMeliGhT trial is designed to assess the safety and efficacy of OCU400 in slowing or halting the progression of RP. Data updates from Phase 1/2 trials for RP and Leber congenital amaurosis (search) (LCA) will also be presented.
Geographic Atrophy: OCU410 Phase 1/2 ArMaDa Trial
Preliminary safety and efficacy data from the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy (search) will be a key highlight. GA is an advanced form of age-related macular degeneration (AMD) that causes irreversible vision loss. The ArMaDa trial is evaluating the potential of OCU410 to address the unmet medical need for effective GA treatments.
Stargardt Disease: OCU410ST Phase 1/2 GARDian Trial
Ocugen will also present a clinical update on the Phase 1/2 GARDian clinical trial, which is investigating OCU410ST for Stargardt disease (search). Stargardt disease is an inherited form of macular degeneration that affects central vision, typically starting in childhood or adolescence. The GARDian study aims to assess the safety and potential efficacy of OCU410ST in patients with Stargardt disease.
OCU200 for Diabetic Macular Edema
In addition to gene therapy programs, Ocugen will provide background information on its biologic candidate, OCU200, for diabetic macular edema (search) (DME). DME is a complication of diabetes that causes swelling in the retina, leading to vision impairment. The company plans to initiate a Phase 1 clinical trial for OCU200 this quarter, marking a significant step in its development.
The Clinical Showcase will feature presentations from Ocugen's leadership team, including Dr. Shankar Musunuri, Chairman, CEO & Co-founder; Dr. Huma Qamar, Chief Medical Officer; and Dr. Arun Upadhyay, Chief Scientific Officer & Head of R&D. Study investigators, including Dr. Benjamin Bakall, Dr. Lejla Vajzovic, and Dr. Syed M. Shah, will also participate. The program will conclude with a patient panel representing participants in Ocugen’s ongoing clinical trials, offering valuable perspectives on their experiences.